title: Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure.
abstract: The burden of heart failure (HF) increases worldwide with an aging population, and there is a high unmet medical need in both, heart failure with reduced ejection fraction (HFrEF) and with preserved ejection fraction (HFpEF). The nitric oxide (NO) pathway is a key regulator in the cardiovascular system and modulates vascular tone and myocardial performance. Disruption of the NO-cyclic guanosine monophosphate (cGMP) signaling axis and impaired cGMP formation by endothelial dysfunction could lead to vasotone dysregulation, vascular and ventricular stiffening, fibrosis, and hypertrophy resulting in a decline of heart as well as kidney function. Therefore, the NO-cGMP pathway is a treatment target in heart failure. Exogenous NO donors such as nitrates have long been used for treatment of cardiovascular diseases but turned out to be limited by increased oxidative stress and tolerance. More recently, novel classes of drugs were discovered which enhance cGMP production by targeting the NO receptor soluble guanylate cyclase (sGC). These compounds, the so-called sGC stimulators and sGC activators, are able to increase the enzymatic activity of sGC to generate cGMP independently of NO and have been developed to target this important signaling cascade in the cardiovascular system.This review will focus on the role of sGC in cardiovascular (CV) physiology and disease and the pharmacological potential of sGC stimulators and sGC activators therein. Preclinical data will be reviewed and summarized, and available clinical data with riociguat and vericiguat, novel direct sGC stimulators, will be presented. Vericiguat is currently being studied in a Phase III clinical program for the treatment of heart failure with reduced ejection fraction (HFrEF).
authors.affiliation: Bayer AG, Wuppertal, 42069, Germany. stefanie.breitenstein@bayer.com.
authors.forename: Stefanie
authors.initials: S
authors.lastname: Breitenstein
authors.affiliation: Bayer AG, Wuppertal, 42069, Germany.
authors.forename: Lothar
authors.initials: L
authors.lastname: Roessig
authors.affiliation: Bayer AG, Wuppertal, 42069, Germany.
authors.forename: Peter
authors.initials: P
authors.lastname: Sandner
authors.affiliation: Bayer AG, Wuppertal, 42069, Germany.
authors.forename: Kelly S
authors.initials: KS
authors.lastname: Lewis
mesh_terms: D001565:Benzoates / Q000627:therapeutic use*; D006152:Cyclic GMP / Q000378:metabolism; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D006574:Heterocyclic Compounds, 2-Ring / Q000627:therapeutic use*; D006801:Humans; D009569:Nitric Oxide / Q000378:metabolism; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D015398:Signal Transduction; D000071756:Soluble Guanylyl Cyclase / Q000378:metabolism*; D013318:Stroke Volume
chemical_list: D001565:Benzoates; D006574:Heterocyclic Compounds, 2-Ring; D011720:Pyrazoles; D011743:Pyrimidines; D009569:Nitric Oxide; C480588:BAY 58-2667; D000071756:Soluble Guanylyl Cyclase; D006152:Cyclic GMP; C000603960:vericiguat; C542595:riociguat
keywords: Cardiovascular; Cinaciguat; Cyclic guanosine monophosphate (cGMP); Heart failure (HF); Nitric oxide (NO); Riociguat; Soluble guanylate cyclase (sGC); Vericiguat; sGC activator; sGC stimulator